1 / 1
Ipamorelin 5 mg is a selective growth hormone–releasing peptide (GHRP) that stimulates endogenous growth hormone secretion by acting on the pituitary gland. It is known for its specificity, producing minimal stimulation of cortisol or prolactin compared to other peptides in the same category. Ipamorelin is commonly used in research related to growth hormone release, recovery, sleep quality, and body composition. It is typically supplied as a 5 mg lyophilized powder.
Prior to use, Ipamorelin must be reconstituted. A common reconstitution method is to add 3 mL of bacteriostatic water to a 5 mg vial, resulting in a final concentration of approximately 1.67 mg/mL (1,670 mcg/mL).
When using a U-100 insulin syringe, each unit corresponds to roughly 16–17 mcg. Reconstitution should be done slowly by injecting the diluent down the side of the vial to avoid foaming or peptide degradation. The vial should be gently swirled until fully dissolved and then stored under refrigeration.
Dosing is generally approached in a gradual manner to assess tolerance. Typical starting amounts are around 100 mcg per day, with many protocols increasing to 150–200 mcg daily. A commonly maintained research dose is 200 mcg per day, while some protocols allow for increases up to 250 mcg daily depending on individual response and study design.
Ipamorelin is most often administered once daily, though the total daily dose may be divided into two administrations if desired. For optimal growth hormone release, administration is usually performed in a fasted state, most commonly 30–60 minutes before sleep or at least 1–2 hours before meals.
A standard research cycle length ranges from 8 to 12 weeks, followed by a rest period of approximately 2–4 weeks to allow physiological markers to return to baseline.
Once reconstituted, Ipamorelin should be stored under refrigeration at 2–8 °C and is generally recommended to be used within about four weeks to maintain stability and potency.
Ipamorelin 5 mg is a selective growth hormone–releasing peptide (GHRP) that stimulates endogenous growth hormone secretion by acting on the pituitary gland. It offers high specificity with minimal stimulation of cortisol or prolactin compared to other GHRP category peptides.
It is reconstituted by slowly adding 3 mL of bacteriostatic water down the side of a 5 mg vial to prevent foaming or degradation. This creates a concentration of approximately 1.67 mg/mL (1,670 mcg/mL). Gently swirl until fully dissolved.
Research protocols usually begin with a starting dose of around 100 mcg daily to assess tolerance, increasing to a standard maintenance dose of 150–200 mcg daily, with some protocols allowing up to 250 mcg daily.
For optimal growth hormone release, administration is best performed in a fasted state. Common timing includes 30–60 minutes prior to sleep or at least 1–2 hours before meals, either once daily or split into two administrations.
A standard research cycle typically lasts between 8 and 12 weeks. This is followed by a rest period of about 2 to 4 weeks to allow physiological markers to return to baseline.
Once reconstituted, the vial must be stored under refrigeration at 2–8 °C. It is recommended to be used within approximately four weeks to maintain maximum stability and potency.
